Kamada Ltd.

Kamada Ltd. is a specialty pharmaceutical company that manufactures and sells plasma-derived protein therapeutics. Its product portfolio includes KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for preventing Cytomegalovirus disease in transplant patients, VARIZIG for varicella post-exposure prophylaxis, WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization, HEPAGAM B for hepatitis B prevention, GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD), KAMRHO (D) IM for hemolytic disease of newborns, and antiserums for snake bites. The company also distributes biopharmaceuticals in Israel, such as BRAMITOB for chronic pulmonary infection, FOSTER for asthma, TRIMBOW for COPD, and others for various conditions including rheumatoid arthritis, immunodeficiency, and hemophilia.

Kamada Ltd. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KMDA. Its securities trade in US Dollars (USD). The company is headquartered in Israel and its stock is accessible to international investors through the US exchange.

Kamada Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing and producing specialized pharmaceutical products, particularly plasma-derived therapies, as well as generic drugs. Its niche in specialty and generic drug manufacturing allows it to address specific medical needs such as rare diseases, transplant-related conditions, and infectious disease prophylaxis.

Kamada Ltd. is based in Israel, as indicated by its country of incorporation. The company serves both domestic and international markets. It distributes its own plasma-derived therapeutics globally, and additionally acts as a distributor for other biopharmaceutical products within Israel. Its product portfolio addresses conditions prevalent in various regions, including rabies prophylaxis, transplant-related cytomegalovirus, and snake bite treatments relevant to its geographic area.

Kamada generates revenue primarily through the manufacture and sale of plasma-derived protein therapeutics. Its product line includes treatments for rabies, cytomegalovirus, varicella, immune thrombocytopenic purpura, hepatitis B, alpha-1 antitrypsin deficiency, hemolytic disease of newborns, and snake bites. Additionally, the company distributes third-party biopharmaceutical products in Israel, such as BRAMITOB, FOSTER, TRIMBOW, and others for respiratory, allergic, and autoimmune conditions. This dual approach of proprietary products and distribution agreements allows Kamada to capture value across multiple therapeutic areas.